Trial Profile

A registrational phase 3 randomized, placebo-controlled superiority trial of SIDIPREV for prevention against C. difficile

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 28 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Oct 2025 New trial record
03 Sep 2025 According to LPOXY Therapeutics media release, the company signed a term sheet with 5Horizons Ventures, in support of a $28 million Series A financing, which will fund LPOXY's registrational STOP-Cdiff (SIDIPREV™ Trial On Prevention of C. difficile Infections) clinical trial.
03 Sep 2025 According to LPOXY Therapeutics media release, this trial is designed under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV. LPOXY aims to launch this trial in Q3 2026 and file for approval in 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com